Tacrine, a drug with therapeutic potential for dementia: post-mortem biochemical evidence.
A review of biochemical findings is presented which support the idea that Alzheimer's disease represents a condition for which tetrahydroaminoacridine (tacrine) may have a beneficial effect. There is evidence that clinical and histopathologic hallmarks of the disease relate to cholinergic and serotonergic dysfunction, with less obvious abnormalities in other neurotransmitters (aspartate, dopamine, gamma-aminobutyrate, glutamate, noradrenaline and somatostatin). Clinically relevant concentrations of tacrine may ameliorate the above presynaptic deficits without producing harmful (neurotoxic) effects of aspartate and glutamate. The disease seems to be associated with an early and clinically relevant degeneration of some neurons with cortical perikarya that release these amino acid transmitters. Studies are now required on the effect of tacrine on postulated harmful peptide-bond hydrolase activity within and around such cells.
Francis
P T
PT
Department of Neurochemistry, University of London, GB.
Bowen
D M
DM
D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D000609:Aminoacridines / Q000627:therapeutic use*; D001921:Brain / Q000378:metabolism*; D006801:Humans; D018377:Neurotransmitter Agents / Q000378:metabolism*; D013619:Tacrine / Q000627:therapeutic use*
D000609:Aminoacridines; D018377:Neurotransmitter Agents; D013619:Tacrine